332 related articles for article (PubMed ID: 34807428)
1. Abrocitinib: First Approval.
Deeks ED; Duggan S
Drugs; 2021 Dec; 81(18):2149-2157. PubMed ID: 34807428
[TBL] [Abstract][Full Text] [Related]
2. Abrocitinib for the treatment of atopic dermatitis.
Crowley EL; Nezamololama N; Papp K; Gooderham MJ
Expert Rev Clin Immunol; 2020 Oct; 16(10):955-962. PubMed ID: 32969750
[TBL] [Abstract][Full Text] [Related]
3. The Efficacy and Safety of Abrocitinib as a Treatment Option for Atopic Dermatitis: A Short Report of the Clinical Data.
Napolitano M; Fabbrocini G; Ruggiero A; Marino V; Nocerino M; Patruno C
Drug Des Devel Ther; 2021; 15():1135-1147. PubMed ID: 33731985
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Simpson EL; Sinclair R; Forman S; Wollenberg A; Aschoff R; Cork M; Bieber T; Thyssen JP; Yosipovitch G; Flohr C; Magnolo N; Maari C; Feeney C; Biswas P; Tatulych S; Valdez H; Rojo R
Lancet; 2020 Jul; 396(10246):255-266. PubMed ID: 32711801
[TBL] [Abstract][Full Text] [Related]
5. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
Simpson EL; Silverberg JI; Nosbaum A; Winthrop K; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Fan H; Farooqui SA; Chan G; Alderfer J; Romero W; Chittuluru K
Am J Clin Dermatol; 2024 Jul; 25(4):639-654. PubMed ID: 38888681
[TBL] [Abstract][Full Text] [Related]
6. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Bauman JN; Doran AC; King-Ahmad A; Sharma R; Walker GS; Lin J; Lin TH; Telliez JB; Tripathy S; Goosen TC; Banfield C; Malhotra BK; Dowty ME
Drug Metab Dispos; 2022 Aug; 50(8):1106-1118. PubMed ID: 35701182
[TBL] [Abstract][Full Text] [Related]
7. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
Nezamololama N; Crowley EL; Gooderham MJ; Papp K
Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
[TBL] [Abstract][Full Text] [Related]
8. Abrocitinib in atopic dermatitis: review of the current literature and clinical trials.
Napolitano M; Fornaro L; Potestio L; Fabbrocini G; Patruno C
Drugs Today (Barc); 2022 Aug; 58(8):373-387. PubMed ID: 35983924
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
[TBL] [Abstract][Full Text] [Related]
10. An evaluation of abrocitinib for moderate-to-severe atopic dermatitis.
Labib A; Yosipovitch G
Expert Rev Clin Immunol; 2022 Nov; 18(11):1107-1118. PubMed ID: 36173402
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Silverberg JI; Simpson EL; Thyssen JP; Gooderham M; Chan G; Feeney C; Biswas P; Valdez H; DiBonaventura M; Nduaka C; Rojo R
JAMA Dermatol; 2020 Aug; 156(8):863-873. PubMed ID: 32492087
[TBL] [Abstract][Full Text] [Related]
12. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
[TBL] [Abstract][Full Text] [Related]
13. Abrocitinib: First Globally Approved Selective Janus Kinase-1 Inhibitor for the Treatment of Atopic Dermatitis.
De SK
Curr Med Chem; 2023; 30(38):4278-4282. PubMed ID: 36797599
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Gooderham MJ; Forman SB; Bissonnette R; Beebe JS; Zhang W; Banfield C; Zhu L; Papacharalambous J; Vincent MS; Peeva E
JAMA Dermatol; 2019 Dec; 155(12):1371-1379. PubMed ID: 31577341
[TBL] [Abstract][Full Text] [Related]
15. Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Soto E; Banfield C; Gupta P; Peterson MC
CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):553-560. PubMed ID: 32830463
[TBL] [Abstract][Full Text] [Related]
16. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.
Perche PO; Cook MK; Feldman SR
Ann Pharmacother; 2023 Jan; 57(1):86-98. PubMed ID: 35587593
[TBL] [Abstract][Full Text] [Related]
17. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
[TBL] [Abstract][Full Text] [Related]
18. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
[TBL] [Abstract][Full Text] [Related]
19. Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Wang EQ; Le V; Winton JA; Tripathy S; Raje S; Wang L; Dowty ME; Malhotra BK
J Clin Pharmacol; 2022 Apr; 62(4):505-519. PubMed ID: 34637151
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]